about
Fifty years of melphalan use in hematopoietic stem cell transplantationChronic diarrhea as the initial clinical manifestation of light-chain amyloidosis with cardiac involvement despite negative duodenal and rectal biopsies.Primary amyloidoma of lung treated with radiation: A rare case report.Tyrosine residues mediate fibril formation in a dynamic light chain dimer interface.Updates in cardiac amyloidosis: a review.Clinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosisAmyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature.Amyloid and the GI tract.High-dose melphalan and autologous stem cell transplantation for systemic light-chain amyloidosis: a single institution retrospective analysis of 40 cases.Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains.Amyloidosis relapsing after autologous stem cell transplantation treated with bortezomib: normalization of detectable serum-free light chains and reversal of tissue damage with improved suitability for transplant.Successful long-term outcome of the first combined heart and kidney transplant in a patient with systemic Al amyloidosis.Clinical profile and treatment outcomes of immunoglobulin D associated AL amyloidosis.Amyloidosis presenting in the head and neck: a report of two cases.Guidelines on the diagnosis and investigation of AL amyloidosis.AbstractsResults of autologous stem cell transplantation for AL amyloidosis in one Czech centerHereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation
P2860
Q26824498-5E52139B-59D7-4793-B612-5724F54BF8C0Q33163149-1D7D7A5D-4BFE-46EB-8EA0-50C5475E36A2Q34453149-25A87688-A5A8-4407-AF0B-F6D246B68D25Q36201752-4F54F108-9D42-488C-9431-17038431DE50Q36366356-DEA7D732-F3FA-41F6-96EE-E8FAE6FD0F35Q36779759-39ADF8E7-6189-47B7-8F3C-E9D2B10C0AACQ37086690-C7DD925A-D900-4C5A-B306-2FE0546BCA9BQ37634562-B1179399-568B-4D53-83F2-BC67C48371C9Q37636098-D66FFF41-24E3-4FC9-BEEC-9EABC5733D93Q41021929-75849960-B659-473F-9500-ABEEC7CE1A89Q42160574-DAC8C03C-84CF-4DFC-BA7B-072AA1B9F1C2Q42879120-8C0C7248-FB9E-4BCA-A7D7-64B185F7CD75Q42932124-9F0F41B6-5465-4BC8-A917-FC3654E4558FQ46152268-C84DDCDD-54BC-4216-9220-BD05DF8474A3Q53314979-C4817C52-7C88-41BC-9D30-9704F90FB0ADQ55058605-3DA0D212-4074-4FCB-96B2-A4EF4FCD641CQ57259399-F4B9FE0A-0F2E-46CC-A4A7-21E906598160Q58125071-13BB1143-8BB2-477D-9066-297A8324EB5BQ58853080-B40EFE49-4442-466E-B692-F5A83B7F7E1A
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Perspectives in treatment of AL amyloidosis.
@en
Perspectives in treatment of AL amyloidosis.
@nl
type
label
Perspectives in treatment of AL amyloidosis.
@en
Perspectives in treatment of AL amyloidosis.
@nl
prefLabel
Perspectives in treatment of AL amyloidosis.
@en
Perspectives in treatment of AL amyloidosis.
@nl
P2093
P2860
P1476
Perspectives in treatment of AL amyloidosis.
@en
P2093
Ashutosh D Wechalekar
Julian D Gillmore
Philip N Hawkins
P2860
P304
P356
10.1111/J.1365-2141.2007.06936.X
P407
P577
2007-12-19T00:00:00Z